Extreme Movers: Muse Spark 1.1's picks for 2026-10-30
Muse Spark 1.1 picked NOW, GKOS, ADT, CROX, IOVA for a 1-day horizon. Average directional return: -0.72%. Directions called correctly: 80%.
| Experiment | Extreme Movers |
|---|---|
| Model | Muse Spark 1.1 |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-30 |
| Measured to | 2026-11-02 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.72% |
| Directions called correctly | 80% |
| Benchmark return | -0.09% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | NOW | down | -0.86% | +0.86% | 72% | +0.95% | Yes |
| 2 | GKOS | down | -0.30% | +0.30% | 68% | +0.39% | Yes |
| 3 | ADT | up | +0.05% | +0.05% | 65% | +0.14% | Yes |
| 4 | CROX | up | +0.50% | +0.50% | 62% | +0.59% | Yes |
| 5 | IOVA | up | -5.34% | -5.34% | 58% | -5.25% | No |
The model's market view
Oct 29 close was mixed with sharp single-name dispersion on earnings. Top movers were driven by substantive catalysts: ADT buyout, Glaukos and Crocs earnings beats, Iovance clinical update, ServiceNow earnings miss. Oct 30 premarket is risk-off with Nasdaq futures down on Amazon -6.85% and Intel -25% guidance, suggesting continued pressure on software and selective profit-taking in parabolic med-tech winners. Intraday quotes on Oct 30 are used for reference_price.
Why each pick
NOW
ServiceNow closed Oct 29 at $109.67 down -26.97% on Oct 29, worst day since IPO, after Q3 adjusted EPS miss $1.00 vs $1.02 and lighter Q4 cRPO guide 18.5% vs 20% consensus. Substantive earnings catalyst, volume 76.4M vs 12.5M 20-day average, $6.74B dollar volume. Market cap $160.04B on Oct 29, avg daily traded value $2.25B, price $109.67 prior close above $5 floor. Reference_price is latest intraday $107.92 on Oct 30 from Finnhub, previous close $109.67, down -1.6% intraday, quote is Oct 30 and less than 2 hours old. Continuation down thesis: software derating on AI capex concerns, guidance cut triggers estimate cuts, gap fill unlikely same session. Risk: oversold bounce after -27% may attract dip buyers.
GKOS
Glaukos jumped +33.65% to $242.48 on Oct 29 close, gaining $61.05 from $181.43 prior close, intraday high $243.71 all-time high, on Q3 earnings beat and bullish guidance for iDose TR and iStent. Substantive catalyst with volume 5.41M vs avg 901k. Market cap $14.35B on Oct 29, avg daily traded value $121.84M, price $242.48 passes $5, $1B, $20M floors. Reference_price latest $241.62 on Oct 30 from Finnhub, -0.35% vs prior close, quote from Oct 30 session, less than 3 hours old. Reversal down thesis: parabolic to ATH typically sees profit-taking next session, RSI extreme, JPMorgan $240 target caps. Risk: squeeze continuation if guidance raises estimates further.
ADT
ADT surged +33.20% to $9.87 close on Oct 29 after board approved all-cash $10 per share buyout by Thrive Holdings, $7.6B equity $15.3B EV, 45.6% premium to Oct 27 $6.87 close, go-shop through Nov 28, close Q1 2027. Substantive deal catalyst with hard ceiling at $10. Volume 163.85M vs 20-day avg 15.13M. Market cap $7.21B on Oct 29, avg daily traded value $72.33M, price passes floors. Reference_price latest $9.875 intraday Oct 30 from Finnhub, flat vs prior close, quote Oct 30 morning, fresh. Continuation up thesis: arb spread 1.2% to $10 leaves small drift higher as deal certainty rises, but capped. Risk: spread closes to zero or deal break widens downside.
CROX
Crocs climbed +25.54% to $150.26 close on Oct 29 after Q3 EPS $3.69 vs $3.31 consensus +11.48% surprise, revenue $1.04B +4.6% YoY vs $1.0B expected, raised full-year growth to ~3% with HEYDUDE turnaround ahead of schedule. Substantive earnings catalyst. Market cap $6.94B on Oct 29, avg daily traded value $129.62M, price $150.26 passes floors, 20-day avg volume 1.23M shares. Reference_price latest $151.86 intraday Oct 30 from Finnhub, +1.06% vs prior close, Oct 30 quote fresh. Continuation up thesis: beat and raise plus Barclays upgrade to Overweight $139 target raised, momentum in consumer discretionary. Risk: after +25% single session, intraday reversal likely if market weak.
IOVA
Iovance fell -35.45% to $9.56 close on Oct 29 after updated IOV-LUN-202 lifileucel lung cancer data 24.6% response in 69 patients vs 25.6% earlier, 43.3% wild-type vs 11.4% mutant, filing delayed to 2027. Substantive negative clinical catalyst, but raised 2026 revenue guide $410-420M. Market cap $4.33B on Oct 29, avg daily traded value $82.89M, price $9.56 above $5 floor, volume 59M vs 11.7M average. Reference_price latest $8.465 intraday Oct 30 from Finnhub, -11.45% vs prior close, Oct 30 morning quote, indicates premarket continuation then bounce setup. Reversal up thesis: oversold biotech after 35% drop often mean-reverts, short interest high, guidance raise supports floor. Risk: biomarker strategy uncertainty keeps selling.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Grok 4.7 | GKOS, CVNA, GEN, NOW, FTNT | +3.64% | 80% |
| Perplexity | INTC, RDDT, TWLO, REGN, AN | +2.02% | 80% |
| Claude Opus 5.5 | GOOGL, NOW, HII, TXT, CVNA | +1.38% | 60% |
| DeepSeek | ADT, GEN, CVNA, GOOGL, NCLH | -1.63% | 40% |
| Gemini 3 Pro | ADT, GKOS, CROX, NOW, FTNT | -1.08% | 40% |
| GPT-6 | GKOS, ALNY, CROX, FTNT, NOW | +3.07% | 60% |
Written up on ForecastNest Insights: Extreme Movers: Muse Spark 1.1's picks for 2026-10-30.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.